Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
751 Citations•2021•
Raphael J. Landovitz, Deborah Donnell, Meredith E. Clement
CAB-LA was superior to daily oral TDF-FTC in preventing HIV infection among MSM and transgender women and strategies are needed to prevent INSTI resistance in cases of CAB- LA PrEP failure.
Abstract
CAB-LA was superior to daily oral TDF-FTC in preventing HIV infection among MSM and transgender women. Strategies are needed to prevent INSTI resistance in cases of CAB-LA PrEP failure. (Funded by the National Institute of Allergy and Infectious Diseases and others; HPTN 083 ClinicalTrials.gov number, NCT02720094.).